Loading…
Employees: 64
Size Hanx Biopharmaceuticals (Wuhan) (3378.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $469M, the 770th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$27.00 on 6 Nov 2026.
Performance Over six months the shares fell 12.8%, against -5.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 9th lowest of 20 in its peer set.
Capital Return on invested capital runs 48.3 points below its cost of capital (5.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -HK$7.84M | -HK$6.94M | -HK$5.94M | -HK$1.15M | -HK$1.01M |
| EBITDA | -HK$152M | -HK$135M | -HK$125M | -HK$69.6M | -HK$86.8M |
| Net income | -HK$146M | -HK$142M | -HK$126M | -HK$84.0M | -HK$33.0M |
| Free cash flow | -HK$94.2M | -HK$114M | -HK$117M | -HK$57.6M | -HK$53.4M |
| Capital expenditure | HK$460,289 | HK$2.11M | HK$6.73M | HK$5.28M | HK$998,912 |
| Total debt | n/a | HK$62.2M | HK$153M | HK$16.5M | HK$459,201 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3378.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.0% | -14.6% | 2nd highest of 21 |
| 6-month return | -12.8% | -5.3% | 9th lowest of 20 |
| Distance from 52-week high | -20.1% | -40.0% | highest of 21 |
| ROIC minus cost of capital | -48.3 pp | -10.9 pp | 4th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | 5.2× | 6.0% | -62.3% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 2.5× | -14.9% | -36.1% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 18.0× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | 258.1× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | 11.4× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | 12.1× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | 8,168.1× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 5.2× | 15.2% | +0.5% |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | 22.4× | 31.8% | -3.3% |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 2.3× | 18.2% | +7.3% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | 12.1× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | 5.9× | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | 28.3× | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | 3.8× | n/a | n/a |